Sunshine Biopharma, Inc. (SBFMW) 股票分析

公司概述

Sunshine Biopharma, Inc. operates as a pharmaceutical entity dedicated to the research and development of life-saving medicines across diverse therapeutic areas, with a specific focus on oncology and antivirals within the United States and Canadian markets. The company functions through its Prescription Generic Pharmaceuticals and Nonprescription segments to deliver its product portfolio. While specific sector and industry classifications are not provided in the available data, the firm's operational scope places it within the broader biotechnology and healthcare infrastructure, serving a critical role in providing essential medications. The company's financial scale is characterized by a trailing twelve-month revenue of $36.31 million and an employee count that is not publicly disclosed in the current dataset. The market capitalization and revenue figures indicate a small-cap operational profile, suggesting that Sunshine Biopharma functions as a specialized player rather than a large-scale diversified conglomerate, which often implies higher sensitivity to regulatory shifts and R&D outcomes in the pharmaceutical landscape.

财务健康

The company reported a revenue of $36.31 million over the trailing twelve months, yet this gross income was accompanied by a net income loss of $5,975,352 and an EBITDA of $-4,146,712. The significant gap between the positive revenue figure and the substantial net loss reveals a cost structure where operating expenses, likely driven by research, development, and administrative overhead, far exceed the gross profit generated from sales. This financial reality is further underscored by a free cash flow of $-4,632,801, indicating that the company is burning through cash reserves to fund its operations and growth initiatives rather than generating cash from core activities. Margin analysis shows a gross margin of 33.8%, while the operating margin stands at -19.3% and the profit margin is -16.5%, illustrating that while the cost of goods sold is relatively controlled, overhead costs are aggressively consuming profits. On the balance sheet, the company holds $9.12 million in cash against a debt obligation of $812,422, resulting in a debt-to-equity ratio of 3.53, which suggests a leveraged position where equity is significantly smaller than the total debt load. Despite the high leverage, the current ratio of 4.17 indicates strong short-term liquidity, as the company possesses more than four times the current assets needed to cover its current liabilities. Return on equity is recorded at -25.7% and return on assets at -9.2%, metrics that reflect that management is currently unable to generate positive returns on the capital invested in the business.

估值评估

Trailing and forward P/E ratios are not available for Sunshine Biopharma, Inc., as the company is reporting net losses which prevent the calculation of a traditional earnings-based multiple. In the absence of a positive earnings stream, the price-to-book ratio of 0.02 serves as a primary valuation indicator, suggesting the market values the company at a fraction of its book value. The lack of a price-to-sales ratio and EV/EBITDA metrics in the available data highlights the limitations of applying standard valuation models to a loss-making biopharmaceutical firm. Regarding trading range, the 52-week high and low are both recorded at $0.13, meaning the stock is currently trading exactly at its annual range boundaries with no deviation observed within the past year. The beta value of 1.60 indicates that the stock exhibits higher price volatility relative to the broader market, moving with greater intensity than the average equity instrument during periods of market fluctuation.

Growth & Income

Revenue growth year-over-year stands at -10.6%, while earnings growth is not calculable due to the company's loss-making status. The negative revenue trajectory suggests a contraction in sales volume or pricing power, whereas the absence of earnings growth reinforces the financial challenges inherent in the early or late-stage development phases of the pharmaceutical sector. As the company does not pay dividends, with no dividend yield or payout ratio reported, it retains all available earnings to reinvest into research and development efforts rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined by a focus on capital preservation and future product potential rather than current profitability or income generation for investors.